Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

137.48
0.0000
Post-market: 137.510.0300+0.02%19:51 EDT
Volume:2.42M
Turnover:334.25M
Market Cap:262.31B
PE:20.78
High:139.43
Open:138.76
Low:137.46
Close:137.48
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:0.57
T/O Rate:0.13%
Dividend:4.67
Dividend Rate:3.39%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.31
PE(LYR):19.23

Loading ...

Novartis announces new data from PSMAddition

TIPRANKS
·
May 18

Dyne Can Unlock Value in Two Drug Prospects, RBC Says

MT Newswires Live
·
May 13

Novartis breaks ground on radioligand therapy manufacturing site in Texas

TIPRANKS
·
May 08

Novartis Starts Construction on Texas Cancer Therapy Manufacturing Facility

MT Newswires Live
·
May 08

Global Pharmaceutical Giants Report Robust Earnings, Increasing Investments in China

Deep News
·
May 07

Novartis Gains Canada Nod for Fabhalta in Rare Kidney Disease

MT Newswires Live
·
May 02

Novartis to Build Drug Ingredient Manufacturing Site in North Carolina

Dow Jones
·
Apr 30

Novartis AG reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Apr 28

Novartis Shares Decline Following Disappointing Quarterly Results

Deep News
·
Apr 28

US Equity Futures Mostly Lower Pre-Bell Amid Continued Middle East Standoff, AI Spending Concerns

MT Newswires Live
·
Apr 28

Sector Update: Health Care

MT Newswires Live
·
Apr 28

Novartis reports Q1 core EPS $1.99 vs. $2.28 last year

TIPRANKS
·
Apr 28

Novartis Chief Predicts Trump's Drug Pricing Policy to Unfold Over Next Year and a Half

Deep News
·
Apr 28

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

Dow Jones
·
Apr 28

Novartis Misses Quarterly Profit Estimates on Steep Generic Erosion

Reuters
·
Apr 28

Novartis Reaffirms FY2026 Outlook; Net Sales to Grow Low Single-Digit, Core Operating Income to Decline Low Single-Digit

Benzinga Earnings
·
Apr 28

Novartis Q1 Adj. EPS $1.99 Misses $2.13 Estimate, Sales $13.113B Miss $13.648B Estimate

Benzinga Earnings
·
Apr 28

Novartis Expected to Take Earnings Hit From Patent Expirations -- Earnings Preview

Dow Jones
·
Apr 27

Novartis announces EC approved Rhapsido for CSU

TIPRANKS
·
Apr 27

Novartis Secures European Commission Approval for Oral Urticaria Treatment

MT Newswires Live
·
Apr 27